The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
- 1 September 2014
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 134 (3), 462-467
- https://doi.org/10.1016/j.ygyno.2014.07.004
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?Gynecologic Oncology, 2012
- An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)Gynecologic Oncology, 2012
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysisGynecologic Oncology, 2006
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group StudyGynecologic Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian CancerObstetrics & Gynecology, 2006
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is There a Correlation with “Biological Aggressiveness” and Survival?Gynecologic Oncology, 2001
- Adjuvant chemotherapyCancer, 1978